Evatanepag (sodium)

• UNSPSC Description:

  Evatanepag sodium is a non-prostanoid, potent and selective EP2 receptor agonist. Evatanepag sodium can induce local bone formation in vivo. Evatanepag sodium can be used in the research of fractures, bone defects, asthma[1][2].

• Target Antigen:

  Prostaglandin Receptor

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein

• Field of Research:

  Endocrinology; Inflammation/Immunology; Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/evatanepag-sodium.html

• Smiles:

  O=C(O[Na])COC1=CC=CC(CN(CC2=CC=C(C(C)(C)C)C=C2)S(=O)(C3=CC=CN=C3)=O)=C1

• Molecular Weight:

  490.55

• References & Citations:

  [1]Cameron KO, et al. Discovery of CP-533536: an EP2 receptor selective prostaglandin E2 (PGE2) agonist that induces local bone formation. Bioorg Med Chem Lett. 2009 Apr 1;19(7):2075-8.|[2]Judith Plaza, et al. In Vitro and In Vivo Validation of EP2-Receptor Agonism to Selectively Achieve Inhibition of Mast Cell Activity. Allergy Asthma Immunol Res. 2020 Jul;12(4):712-728. |[3]V M Paralkar, et al. An EP2 receptor-selective prostaglandin E2 agonist induces bone healing. Proc Natl Acad Sci U S A. 2003 May 27;100(11):6736-40.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  223490-49-1